Advertisement

Advertisement

Lung Cancer
Immunotherapy

Immunomodulatory Effects of Neoadjuvant Nivolumab, Chemotherapy in NSCLC

The immunomodulatory effects of neoadjuvant immune-based treatments for non–small cell lung cancer (NSCLC) are becoming clearer, in part due to data presented by Schmidt et al at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting (Abstract 962). The first integrated analysis of...

lung cancer
immunotherapy

Stephanie T. Schmidt, PhD, on NSCLC: The Immunomodulatory Impact of Neoadjuvant Chemotherapy and Immune-Based Treatments

Stephanie T. Schmidt, PhD, of The University of Texas MD Anderson Cancer Center, discusses the first integrated examination of the immunomodulatory effects of neoadjuvant chemotherapy, nivolumab, and nivolumab plus chemotherapy in resected non–small cell lung cancer (Abstract 962).

Lung Cancer

UKLS Trial Meta-analysis Confirms Mortality Reduction With Low-Dose CT Screening for Lung Cancer

Low-dose lung cancer screening by computed tomography (CT) is associated with a 16% relative reduction in lung cancer mortality over no lung cancer screening of high-risk individuals, based on a meta-analysis conducted by investigators with the United Kingdom Lung Cancer Screening (UKLS) trial.1...

Lung Cancer

T-DXd Makes Inroads in the Treatment of HER2-Mutant NSCLC

Previously treated patients with HER2-positive non–small cell lung cancer (NSCLC) achieved encouraging response rates and duration of response to the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) in the phase II DESTINY-Lung01 trial. These results were reported at the European...

Lung Cancer
Breast Cancer

Can SBRT to Selected Sites of Limited Progression or Oligoprogression Extend Progression-Free Survival in Advanced Lung Cancer but Not Breast Cancer?

Stereotactic body radiation therapy (SBRT) lengthens progression-free survival for patients with advanced lung cancer who have oligoprogression (ie, tumors that have not been fully responsive to systemic chemotherapy or immunotherapy), according to an interim analysis of the CURB oligoprogression...

Lung Cancer

Durable Responses in Metastatic NSCLC: Are We Getting Closer to a Cure?

In the United States, the incidence-based mortality related to non–small cell lung cancer (NSCLC) has decreased by approximately 3% each year since 2008 in men; during the same period, the mortality in women decreased by 2% to 4% annually.1 Although multiple factors are likely responsible for the...

Lung Cancer

2021 State of Lung Cancer Report Finds Survival Has Increased but Remains Significantly Lower for People of Color

The new 2021 State of Lung Cancer report reveals that the 5-year survival rate for lung cancer increased from 14.5% nationally to 23.7%, yet it remains significantly lower among communities of color. The American Lung Association’s fourth annual report also highlights how the toll of lung cancer...

Lung Cancer
COVID-19

French Study Finds COVID-19 Vaccine Effective in Patients With Lung Cancer

In a new study published by Gounant et al in the Journal of Thoracic Oncology, researchers from France showed that SARS–CoV-2 vaccines are safe and effective in patients with thoracic cancer, most of whom are immunized after two doses. A third shot given to 11% of patients with persistent low...

Lung Cancer

The Worst Part of Having Cancer Was the Guilt

When I was diagnosed with small cell lung cancer in 1992, at age 38, I remember thinking, “I wish I had breast cancer.” Breast cancer elicits such sympathy from people. A diagnosis of small cell lung cancer mainly gets you stern looks of disapproval and disappointment. There is so much stigma...

Lung Cancer

IMpower010: Adjuvant Atezolizumab Improves Disease-Free Survival and NSCLC Relapse in Patients Whose Tumors Express PD-L1

Adjuvant immunotherapy with atezolizumab after standard chemotherapy improved disease-free survival and time to locoregional and distant relapse compared with best supportive care in prespecified subgroups of patients with stage II to IIIA non–small cell lung cancer (NSCLC), according to an...

Lung Cancer
Genomics/Genetics

Adjuvant Gefitinib vs Cisplatin/Vinorelbine for Completely Resected EGFR-Mutant Stage II to IIIA NSCLC

In the Japanese phase III IMPACT trial reported in the Journal of Clinical Oncology, Tada et al found that adjuvant gefitinib did not improve disease-free survival vs cisplatin/vinorelbine in patients with completely resected stage II to IIIA EGFR-mutant non–small cell lung cancer (NSCLC). In the...

Lung Cancer

NSCLC in the United States: Update on Incidence, Prevalence, and Survival

In a study reported in JAMA Oncology, Apar Kishor Ganti, MD, MS, and colleagues found that the incidence of non–small cell lung cancer (NSCLC) has decreased in the United States in recent years. They also found that prevalence has increased, likely in association with more effective treatment and...

breast cancer
lung cancer
issues in oncology

Matthew Manning, MD, on Resolving Racial Disparities in the Treatment of Breast and Lung Cancers

Matthew Manning, MD, of Cone Health Cancer Center, discusses findings that showed changes to the way cancer care is delivered may help eliminate racial disparities in survival among patients with early-stage lung and breast cancers. Identifying and addressing obstacles that kept patients from finishing radiation treatments for cancer were associated with improved 5-year survival rates for all patients (Abstract 53).

Lung Cancer
COVID-19

Study Evaluates Virtual vs In-Person Visits and Access to Lung Cancer Screening

Findings from a novel telemedicine effort to screen patients for lung cancer screening during the COVID-19 pandemic show that virtual single-visit screenings may be just as effective as single-visit screenings done in person, according to a study presented by Magarinos et al at the American College ...

breast cancer
lung cancer

C. Jillian Tsai, MD, PhD, on Using Radiotherapy to Thwart Tumor Growth in Advanced Cancers

C. Jillian Tsai, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses results from the first randomized trial of stereotactic body radiation therapy (SBRT) to treat oligoprogressive, metastatic lung and breast cancers. The standard of care for patients with these types of tumors is to switch to a different systemic treatment. Adding local therapy such as SBRT may help treat drug-resistant lesions (Abstract LBA3).  

Lung Cancer
Immunotherapy

Nivolumab for Relapsed Malignant Mesothelioma: Improvements in Progression-Free and Overall Survival

In the phase III CONFIRM trial reported in The Lancet Oncology, Dean A. Fennell, FRCP, PhD, and colleagues found that nivolumab improved progression-free and overall survival vs placebo in patients with relapsed malignant mesothelioma. In October 2020, the combination of nivolumab and ipilimumab...

Breast Cancer
Lung Cancer
Issues in Oncology

ACCURE Trial Aims to Eliminate Disparities in Survival in Black and White Patients With Early-Stage Lung and Breast Cancers

A study presented by Manning et al at the 2021 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract 53) showed that interventions to help Black patients overcome obstacles to completion of treatment can impact disparities in survival outcomes between Black and White patients...

Lung Cancer

Having Stage IV Lung Cancer Has Refocused My Life

The first indication I had stage IV lung cancer was a persistent cough during the beginning of the cold-and-flu season in the fall of 2013. I was 35 years old, never smoked, and in otherwise excellent health, so I ignored the cough for several months until I noticed my breathing had also become...

Lung Cancer
Genomics/Genetics

Mobocertinib for Previously Treated Advanced NSCLC With EGFR Exon 20 Insertion Mutations

On September 15, 2021, the kinase inhibitor mobocertinib was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for adults with locally advanced or metastatic non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, as detected by an FDA-approved test,...

Lung Cancer

Pretreatment Levels of Circulating Tumor DNA May Predict Long-Term Survival in NSCLC

Pretreatment circulating tumor DNA (ctDNA) levels in patients with non–small cell lung cancer (NSCLC) appear to be a more accurate predictor of long-term survival than classic survival surrogates, according to research presented during the International Association for the Study of Lung Cancer...

Lung Cancer

POSEIDON Trial: Dual Checkpoint Blockade Plus Chemotherapy Improves Survival in First-Line Metastatic NSCLC

The combination of dual checkpoint inhibition plus chemotherapy could be the new standard of care in first-line metastatic non–small cell lung cancer (NSCLC), according to data presented during the International Association for the Study of Lung Cancer (IASLC) 2021 World Conference on Lung Cancer.1 ...

Lung Cancer

Phase II Trial Finds Atezolizumab of Benefit in Patients With Lung Cancer and Brain Metastases

Patients with non–small cell lung cancer (NSCLC) and brain metastasis derived significant benefit from treatment with the monoclonal antibody atezolizumab plus chemotherapy, according to the multicenter phase II Atezo-Brain trial.1 The study was presented at the International Association for the...

Lung Cancer

Survey Shows Disparities in Biomarker Testing Among Underserved Patients With Lung Cancer

Recent advances in cancer genomics and targeted therapies have changed the treatment landscape for lung cancer, but disparities in access to precision medicine remain, according to data presented during the International Association for the Study of Lung Cancer (IASLC) 2021 World Conference on Lung ...

Lung Cancer
Genomics/Genetics

Mobocertinib for Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic NSCLC

In a phase I/II trial reported in JAMA Oncology, Caicun Zhou, PhD, MD, and colleagues found that mobocertinib, a first-in-class oral kinase inhibitor, produced durable responses in platinum-pretreated patients with EGFR exon 20 insertion–positive metastatic non–small cell lung cancer (NSCLC).  The...

Lung Cancer
Genomics/Genetics

Second-Line Sotorasib Plus Afatinib for KRAS-Mutant NSCLC

The combination of the KRAS inhibitor sotorasib with afatinib, a pan-ErbB tyrosine kinase inhibitor, was feasible in treating patients with non–small cell lung cancer (NSCLC) and mutated KRAS whose disease had progressed on prior therapies, including KRAS inhibitors alone, according to interim...

Lung Cancer

Can Inhibition of the Aurora Kinase A Protein Help Overcome Resistance to KRAS Inhibition in Patients With Lung Cancer?

In preclinical models, combining an investigational Aurora kinase A (AURKA) inhibitor with a KRAS inhibitor or a WEE1 inhibitor showed efficacy against lung cancer cells with intrinsic or acquired resistance to KRAS inhibition, according to results presented by Lee et al at the AACR-NCI-EORTC...

Lung Cancer
Immunotherapy

FDA Approves Atezolizumab as Adjuvant Treatment for NSCLC

On October 15, the U.S. Food and Drug Administration (FDA) approved atezolizumab (Tecentriq) for adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II to IIIA non–small cell lung cancer (NSCLC) whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as...

Lung Cancer
Genomics/Genetics

Genomic Profiling of Lung Adenocarcinoma in Never-Smokers vs Smokers

In a study reported in the Journal of Clinical Oncology, Devarakonda et al found that never-smokers with lung adenocarcinoma had a high frequency of RTK/RAS/RAF pathway driver alterations—similar to smokers with lung adenocarcinoma—but also harbored a significantly higher total frequency of...

Lung Cancer
Immunotherapy

Neoadjuvant Atezolizumab Under Study in Mesothelioma

Neoadjuvant atezolizumab combined with pemetrexed and cisplatin, with maintenance atezolizumab, proved to be safe and feasible, offering a hint of benefit in patients with resectable pleural mesothelioma, in a small multicenter study presented at the International Association for the Study of Lung...

Lung Cancer

Expert Point of View: Charles M. Rudin, MD, PhD

Charles M. Rudin, MD, PhD, Hassenfeld Professor and Chief of the Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, commented that although ATLANTIS1 “unfortunately joins the ranks of negative phase III studies in patients with recurrent small cell lung cancer,” there are “some...

Lung Cancer

Benefits Seen With Lurbinectedin Plus Doxorubicin in Small Cell Lung Cancer—but Primary Endpoint Missed

As a second-line treatment for patients with small cell lung cancer, lurbinectedin plus doxorubicin failed to improve overall survival in the multicenter ATLANTIS trial but did provide other benefits, including better tolerability, researchers reported at the 2021 World Conference on Lung Cancer,...

Lung Cancer
Immunotherapy

Expert Point of View: Ichiro Yoshino, MD, PhD

Ichiro Yoshino, MD, PhD, Professor and Chairman of the Department of General Thoracic Surgery, Chiba University Graduate School of Medicine, Japan, reviewed the finer details of the IMpower010 exploratory analysis.1 He maintained that atezolizumab’s benefit does, indeed, seem to favor some patient...

Lung Cancer
Immunotherapy

IMpower010: Benefits Observed With Atezolizumab Regardless of Stage, Type of Prior Treatment

In an exploratory analysis of the pivotal phase III IMpower010 trial in stage II–IIIA non–small cell lung cancer (NSCLC), continued treatment with the monoclonal antibody atezolizumab after surgery and chemotherapy improved disease-free survival regardless of the type of surgery or chemotherapy...

Lung Cancer

Study Finds Medicaid Expansion May Be Associated With Decrease in Early Lung Cancer Mortality

Medicare expansion under the Affordable Care Act may have improved outcomes for patients with lung cancer, the leading cause of cancer death in the United States, according to data presented at the 2021 ASCO Quality Care Symposium.1 The National Cancer Database analysis of nearly 12,000 patients...

Lung Cancer
Immunotherapy

Jyoti Patel, MD, Offers Thoughts on Maintenance Durvalumab Utilization

Study discussant Jyoti Patel, MD, Medical Director of Thoracic Oncology and Assistant Director for Clinical Research at the Lurie Cancer Center of Northwestern University, Chicago, called the research “important for many reasons.” Although the study analyzed data from both open and closed claims,...

Lung Cancer
Immunotherapy

Maintenance Durvalumab: Increased Utilization May Improve Outcomes in NSCLC

Maintenance durvalumab, the standard-of-care treatment for patients with unresectable stage III non–small cell lung cancer (NSCLC), remains significantly underutilized, according to data presented at the International Association for the Study of Lung Cancer (IASLC) 2021 World Conference on Lung...

Lung Cancer
Immunotherapy

Black Patients With Advanced NSCLC Receiving Immunotherapy May Have a Lower Risk of Death Than White Patients

Collectively, Black Americans have the highest death rate and shortest survival of any racial/ethnic group in the United States for most cancers; Black men also have the highest cancer incidence rate. Despite improvements in survival disparities between Black and White Americans in specific cancers ...

Lung Cancer
Immunotherapy

Adjuvant Atezolizumab Following Adjuvant Chemotherapy for Resected Stage IB to IIIA NSCLC

In the phase III IMpower010 trial reported in The Lancet, Enriqueta Felip, MD, and colleagues found that the use of adjuvant atezolizumab after adjuvant platinum-based chemotherapy significantly improved disease-free survival vs best supportive care in patients with resected stage II to IIIA...

Issues in Oncology
Cost of Care
Lung Cancer
Gynecologic Cancers

Two Studies Show Health-Care Costs May Impact Follow-up Care After Cancer Screening

Eleven years ago this month, the scans and exams that hold the most power to spot the early signs of cancer became available for free to many American adults through the passing of the Affordable Care Act. Now, two new studies show that when those screening tests reveal potentially troubling signs, ...

lung cancer
health-care policy
legislation

Leticia Nogueira, PhD, MPH, on the Association of Medicaid Expansion and Early Mortality Following Lung Cancer Surgery

Leticia Nogueira, PhD, MPH, of the American Cancer Society, discusses results from a study designed to evaluate the impact of Medicaid expansion under the Affordable Care Act (ACA). In Medicaid-expansion states, mortality among patients after lung cancer surgery decreased from 2.4% before the ACA to 0.8% after the ACA, with no significant change in non–Medicaid-expansion states.

Lung Cancer
Genomics/Genetics

Poziotinib, a Tyrosine Kinase Inhibitor, for HER2 Exon 20–Mutant NSCLC

In a single-center phase II trial reported in the Journal of Clinical Oncology, Elamin et al found that the tyrosine kinase inhibitor poziotinib showed activity in previously treated patients with HER2 exon 20–mutant advanced non–small cell lung cancer (NSCLC). As related by the investigators,...

lung cancer
immunotherapy

Nasser K. Altorki, MD, on NSCLC: Adjuvant Atezolizumab for Stage IB–IIIA Disease

Nasser K. Altorki, MD, of Weill Medical College of Cornell University and NewYork-Presbyterian Hospital, discusses phase III data from the IMpower010 study, which showed that, compared with best supportive care, atezolizumab improved disease-free survival in patients with stage II–IIIA non–small cell lung cancer. These findings applied across most disease stages and most surgery types and chemotherapy regimens, as well as in patients with nodal involvement (Abstract PL02.05).

Lung Cancer

Classifying EGFR Mutations by Structure and Function May Help to Match Patients With NSCLC to More Effective Treatments

Researchers have discovered that grouping EGFR mutations by structure and function provides an accurate framework to match patients with non–small cell lung cancer (NSCLC) to the right drugs. The findings, published by Robichaux et al in Nature, identify four subgroups of mutations and introduce a...

Lung Cancer

Overall Survival With Stereotactic Ablative Radiotherapy for Operable Stage IA NSCLC

As reported in The Lancet Oncology by Chang et al, long-term results of the single-institution revised STARS trial indicate that overall survival in patients receiving stereotactic ablative radiotherapy (SABR) for operable stage IA non–small cell lung cancer (NSCLC) was noninferior to that in a...

lung cancer
genomics/genetics

Robin Cornelissen, MD, PhD, on HER2 Exon 20–Mutated NSCLC: Poziotinib in Treatment-Naive Disease

Robin Cornelissen, MD, PhD, of Erasmus University in Rotterdam, discusses phase II findings from the ZENITH20-4 study, which explored the question of whether poziotinib could benefit patients whose newly diagnosed non–small cell lung cancer harbors EGFR and HER2 exon 20 mutations. Potentially, this novel tyrosine kinase inhibitor may fill an unmet medical need (Abstract LBA46).

Lung Cancer

Patients First

By the time my non–small cell lung cancer was diagnosed in 2004, it had already reached stage IIIB, and I was told there was little that could be done for me. I was 56, a wife, the mother of 3 children, and at the peak of my career as president of Olympian Oil. Although my aunt, brother, and...

lung cancer

Benjamin Besse, MD, PhD, on NSCLC: A Vaccine Under Study to Treat Advanced Disease

Benjamin Besse, MD, PhD, of the Institut Gustave Roussy, discusses final phase III findings from the Atalante-1 trial, which explored the question of whether the OSE2101 vaccine is more beneficial than standard treatment for patients with HLA-A2–positive non–small cell lung cancer after immune checkpoint inhibitors are no longer effective (Abstract LBA47).

Lung Cancer
Immunotherapy

DESTINY-Lung01: Fam-trastuzumab Deruxtecan-nxki in Previously Treated HER2-Mutant NSCLC

In the phase II DESTINY-Lung01 trial, presented at the European Society for Medical Oncology (ESMO) Congress 2021 (Abstract LBA45) and concurrently reported in The New England Journal of Medicine, Bob T. Li, MD, PhD, MPH, and colleagues found that fam-trastuzumab deruxtecan-nxki produced durable...

Lung Cancer
Immunotherapy

Addition of Ramucirumab to Gemcitabine in Second-Line Treatment of Malignant Pleural Mesothelioma

In the Italian phase II RAMES trial reported in The Lancet Oncology, Pinto et al found that the addition of ramucirumab to gemcitabine improved overall survival in the second-line treatment of malignant pleural mesothelioma. As noted by the investigators, “There is a preclinical rationale for...

Lung Cancer

Expert Point of View: Mark G. Kris, MD, FASCO

Mark G. Kris, MD, FASCO, Chief of the Thoracic Oncology Service and the William and Joy Ruane Chair in Thoracic Oncology at Memorial Sloan Kettering Cancer Center, New York, commented on the excitement in the field of lung cancer about the new drugs targeting KRAS. Sotorasib is one of several new...

Advertisement

Advertisement

Advertisement